CYTX - Cytori Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3300
+0.0147 (+4.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3153
Open0.3600
Bid0.3160 x 1100
Ask0.4200 x 900
Day's Range0.3153 - 0.3600
52 Week Range0.3153 - 8.7000
Volume256,213
Avg. Volume275,695
Market Cap2.031M
Beta1.36
PE Ratio (TTM)N/A
EPS (TTM)-5.6350
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Trade prices are not sourced from all markets
  • Benzinga3 days ago

    The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

    Here's a roundup of top developments in the biotech space over the last 24 hours.  Scaling the Peaks (Stocks hitting 52-week highs on Aug. 15) Inspire Medical Systems Inc (NYSE: INSP ) Merck & Co., Inc. ...

  • Benzinga4 days ago

    The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 14) DexCom, Inc. (NASDAQ: DXCM ) Masimo Corporation (NASDAQ: MASI ...

  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of CYTX earnings conference call or presentation 14-Aug-18 9:30pm GMT

    Q2 2018 Cytori Therapeutics Inc Earnings Call

  • Associated Press5 days ago

    Cytori: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 59 cents per share. The developer of cell therapies posted revenue of $1.6 million in the period. In the final minutes of trading on Tuesday, the company's ...

  • GlobeNewswire5 days ago

    Cytori Reports Q2 2018 Business and Financial Results

    SAN DIEGO, Aug. 14, 2018-- Cytori Therapeutics today announced Q2 2018 financial results and provided updates on corporate activities. Q2 2018 net loss was $3.7 million, or $0.59 per share. Operating cash ...

  • Benzinga5 days ago

    The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 13) Iradimed Corp (NASDAQ: IRMD ) SurModics, Inc. (NASDAQ: SRDX ...

  • GlobeNewswire10 days ago

    Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring

    SAN DIEGO, Aug. 09, 2018-- Cytori Therapeutics, Inc. announced publication in the peer-reviewed journal, Stem Cell Research and Therapy, of“ Autologous adipose-derived stromal vascular fraction and scarred ...

  • GlobeNewswire17 days ago

    Cytori to Webcast Second Quarter Financial Results on August 14

    Cytori Therapeutics, Inc. (CYTX) will provide a live webcast of its second quarter financial results and business update on Tuesday, August 14, 2018 at 5:30 PM Eastern Time. Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties.

  • GlobeNewswire26 days ago

    Cytori Announces $6.7 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    Cytori Therapeutics, Inc. (CYTX) announced today that its previously announced rights offering (“the Rights Offering”) expired on July 20, 2018 and such rights are no longer exercisable. Cytori accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $6.7 million in gross proceeds. The results of the Rights Offering and Cytori’s estimates regarding the aggregate gross proceeds of the Rights Offering to be received by Cytori are subject to finalization and verification by Cytori and its subscription agent.

  • GlobeNewswirelast month

    Cytori Reminds Stockholders That Rights Offering Expires on Friday, July 20

    Cytori Therapeutics, Inc. (CYTX) provides a reminder to stockholders that its previously announced rights offering will remain open until 5:00 PM Eastern Time on Friday, July 20, 2018. Rights holders will need to exercise their subscription rights prior to that date and time. The unit pricing remains $1,000 per unit, each unit consisting of one share of Series C Preferred Stock with a face value of $1,000 (and immediately convertible into common stock at a conversion price of the lesser of (a) $1.45 per share and (b) 85% of the lowest daily volume weighted average price for our common stock, as reported at the close of trading by Nasdaq, during the five trading days prior to the expiration of the rights offering (including the expiration date), subject to adjustment) and 621 warrants.

  • GlobeNewswirelast month

    Cytori Reports Sustained Benefit of Cell Therapy in Erectile Dysfunction Trial

    SAN DIEGO, July 09, 2018-- Cytori Therapeutics, Inc. announced publication in the peer-reviewed journal, Urology, of“ A 12- Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-derived ...

  • GlobeNewswire2 months ago

    Cytori Reports Improved Skin Healing in Pivotal Burn Preclinical Study

    Cytori Therapeutics, Inc. (CYTX) announced today the publication of preclinical data from a study using intravenous delivery of Cytori Cell Therapy™ in a model of large burn injury representative of patients being recruited in the ongoing RELIEF clinical trial. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical data supporting the FDA approved United States RELIEF Trial. In the study described in this publication, Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were delivered by intravenous injection in a porcine model of mixed full-and partial thickness burn injury covering approximately 20% of total body surface area in which full thickness burns were treated with a meshed autologous split-thickness skin graft.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...

  • GlobeNewswire2 months ago

    Cytori Therapeutics Reminds Investors of Today’s Deadline to be a Shareholder of Record

    Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”) today issued a reminder to shareholders that the Record Date of its proposed rights offering is June 26, 2018. To be a shareholder of record, ownership of Cytori stock must occur by market close of June 22, 2018 to account for settlement. Under the proposed rights offering, Cytori will distribute one non-transferable subscription right for each share of common stock and Series B Convertible Preferred Stock (on an as-if-converted-to-common-stock basis) held on the record date.  Each right will entitle the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series C Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into shares of Cytori’s common stock at a conversion price of $2.64 per share) and 200 warrants to purchase Cytori’s common stock with an exercise price of $3.17 per share.  The warrants will be exercisable for 30 months after the date of issuance.

  • GlobeNewswire2 months ago

    Cytori Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

    Cytori Therapeutics, Inc. (CYTX) ("Cytori"), today provided an informational update to stockholders regarding its proposed rights offering and the expected key dates and terms relative to the offering. Stockholders are advised to ensure they complete their open market purchases of Cytori common stock by Friday, June 22, 2018 to be considered a stockholder of record on Tuesday, June 26, 2018.  Stockholders or interested parties are advised to direct all questions and informational requests to the contacts listed below. Under the proposed rights offering, Cytori will distribute one non-transferable subscription right for each share of common stock and Series B Convertible Preferred Stock (on an as-if-converted-to-common-stock basis) held on the record date.  Each right will entitle the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series C Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into shares of Cytori’s common stock at a conversion price of $2.64 per share) and 200 warrants to purchase Cytori’s common stock with an exercise price of $3.17 per share.  The warrants will be exercisable for 30 months after the date of issuance.

  • Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic?
    Simply Wall St.3 months ago

    Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic?

    Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medicalRead More...

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...

  • GlobeNewswire3 months ago

    Cytori Therapeutic’s common stock to begin trading on adjusted basis on May 24, following one-for-ten reverse split

    Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced that the Company effected a reverse stock split that became effective on May 23, 2018 at a ratio of one-for-ten, and that the Company’s common stock will commence trading on a post-split basis beginning on May 24, 2018. The Company received the requisite stockholder approval for the reverse stock split on May 18, 2018. The new CUSIP number for the Company’s common stock will be 23283K402.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CYTX earnings conference call or presentation 10-May-18 9:30pm GMT

    Q1 2018 Cytori Therapeutics Inc Earnings Call

  • Business Wire3 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.

    Levi & Korsinsky announces it has commenced an investigation of Cytori Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additional

  • Associated Press3 months ago

    Cytori: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 7 cents. The developer of cell therapies posted revenue of $731,000 in the period. In the final minutes of trading on Thursday, the ...